Pacer Advisors Inc. Boosts Stock Holdings in USANA Health Sciences, Inc. (NYSE:USNA)

Pacer Advisors Inc. grew its position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 8.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 592,001 shares of the company's stock after purchasing an additional 47,745 shares during the period. Pacer Advisors Inc. owned approximately 3.11% of USANA Health Sciences worth $21,247,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Pzena Investment Management LLC lifted its position in USANA Health Sciences by 7.5% during the third quarter. Pzena Investment Management LLC now owns 1,049,610 shares of the company's stock valued at $39,801,000 after purchasing an additional 72,977 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in USANA Health Sciences by 14,068.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company's stock worth $1,472,000 after acquiring an additional 38,547 shares in the last quarter. Unison Advisors LLC bought a new stake in USANA Health Sciences during the third quarter worth approximately $683,000. Assenagon Asset Management S.A. increased its stake in USANA Health Sciences by 13.5% during the third quarter. Assenagon Asset Management S.A. now owns 124,008 shares of the company's stock worth $4,702,000 after acquiring an additional 14,756 shares during the last quarter. Finally, Barclays PLC raised its position in USANA Health Sciences by 111.9% during the third quarter. Barclays PLC now owns 27,737 shares of the company's stock valued at $1,052,000 after purchasing an additional 14,647 shares during the period. 54.25% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on USNA. StockNews.com raised USANA Health Sciences from a "buy" rating to a "strong-buy" rating in a research report on Saturday, December 28th. DA Davidson boosted their price objective on shares of USANA Health Sciences from $35.00 to $38.00 and gave the company a "neutral" rating in a research report on Thursday, January 2nd.

Insider Buying and Selling at USANA Health Sciences

In other news, Director Gilbert A. Fuller sold 675 shares of USANA Health Sciences stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $37.71, for a total transaction of $25,454.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.33% of the stock is currently owned by corporate insiders.

USANA Health Sciences Stock Performance

NYSE USNA traded down $2.27 during trading on Friday, hitting $32.59. The stock had a trading volume of 188,207 shares, compared to its average volume of 105,157. The stock has a market capitalization of $621.17 million, a price-to-earnings ratio of 11.52, a P/E/G ratio of 0.94 and a beta of 0.89. The stock has a 50 day simple moving average of $35.90 and a 200 day simple moving average of $38.06. USANA Health Sciences, Inc. has a one year low of $31.44 and a one year high of $52.75.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.